Enjoy complimentary access to this article collection for a limited time!
-
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Weber JS…Roder H Cancer Immunology Research January 2018. -
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Li C…Zhu Y Cancer Immunology Research February 2018. -
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Iorgulescu JB…Smith TR Cancer Immunology Research September 2018. -
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Richman SA…Milone MC Cancer Immunology Research January 2018. -
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Baumeister SH...Nikiforow S Cancer Immunology Research January 2019. -
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Magee MS…Snook AE Cancer Immunology Research May 2018. -
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Santini FC…Hellmann MD Cancer Immunology Research September 2018.
Cancer Immunology Research Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 446-7289 | E-mail: cancerimmunolres@aacr.org